Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darbepoetin Trial for Neuroprotection in Preterm Infants
NCT03169881Phase 3Completed
- Sponsor
- NICHD Neonatal Research Network
- Start
- Sep 2017
- Primary completion
- Dec 2022
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in neurodevelopmental disorder (NDD) comparing Darbepoetin with Placebo (2 arms). Primary endpoint: Bayley III Composite Cognitive Score. Started Sep 2017; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
neurodevelopmental disorder (NDD)
Beyond the preview
Go deeper on NCT03169881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03169881.